Formulation Development and Evaluation of In-Situ Nasal Gel of Glimepiride

Author(s): Anil Bhavrao Deore*, Avinash B. Gangurde, Vinod A. Bairagi and Vishwanath A. Borse

Abstract: To developed In-situ nasal gel of Glimepiride for sustained release and avoid metabolism by first pass effect in the treatment of diabetic mellitus type II. The In-situ nasal gel of Glimepiride was prepared by using HPMC K-100 M, Poloxamer 188 as a gelling agent and xanthan gum as a sustained relesed agent. The formulation was examined for clarity, pH, gelling temperature, Gelling time, gel strength, spreadability, viscosity, rheological study, drug content, mucoadhesive study and In vitro drug diffusion kinetics. All the prepared formulation was clear solution. Prepared formulations were shown pH between 5.5±0.81 to 6.1±0.97. The nasal mucosa can tolerate the above mention pH of the formulation. Gelling temperature was found between 33.06±1.27 to 37.06±0.54 ᵒC. The gelling time was found between 6.6±1.11 to 24.6±0.82 Sec. Gel strength was found between 17.3±1.28 to 58.6±1.53 Sec. Glimepiride content was obtained in the range between 98.10±10.07 to 98.83±0.92%. The drug release of the all of formulation was found between 43.78±0.21 to 61.42±0.24 %. The F4 formualtion showed a drug diffusion 43.78±0.21% in 6 hrs.,indicated sustained release formulation. The higher concentration of HPMC K-100 M increased the mucoadhesive fraction on goat nasal mucosa. The best formulation F4 provide sustained In-vitro release of the drug over extended period of 6 hrs. The In-situ nasal gel of glimepiride was developed to overcome the first pass metabolism, reduce the dosing frequency and improve patient compliance.

PAGES: 09-17  |  33 VIEWS  54 DOWNLOADS